Switching from reference adalimumab to biosimilar. Assessment of clinical outcomes in psoriasis. Ruiz-Villaverde R, Velasco-Amador JP, Prados-Carmona A, Ruiz-Carrascosa JC, et al. Int J Dermatol 2022 Aug 10. doi: 10.1111/ijd.16399.

Read + Share

Amedeo Smart

Independent Medical Education

Ruiz-Villaverde R, Velasco-Amador JP, Prados-Carmona A, Ruiz-Carrascosa JC, et al. Switching from reference adalimumab to biosimilar. Assessment of clinical outcomes in psoriasis. Int J Dermatol 2022 Aug 10. doi: 10.1111/ijd.16399.
PMID: 35948826